Breaking Finance News

Proteon Therapeutics Inc (NASDAQ:PRTO) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Displaying a price of $8.93, Proteon Therapeutics Inc (NASDAQ:PRTO) traded -2.64% lower on the day. With the last close up 8.24% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. The company has recorded a 50-day moving average of $8.99 and a 200-day moving average of $8.18. 26,322 shares of the stock were exchanged, up from an average trading volume of 14,642

Zacks Investment Research has upgraded Proteon Therapeutics Inc (NASDAQ:PRTO) to Hold in a statement released on 10/12/2016.

On Thursday September 22, 2016, HC Wainwright released a statement on Proteon Therapeutics Inc (NASDAQ:PRTO) upped the target price from $0.00 to $18.00 that suggested an upside of 1.06%.

See Chart Below

Proteon Therapeutics Inc (NASDAQ:PRTO)

Proteon Therapeutics Inc has a 52 week low of $4.90 and a 52 week high of $17.76 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 5 firms have reported on the stock. The consensus target price is $21.40 with 2 firms rating the stock a strong buy, 2 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Proteon Therapeutics Inc (NASDAQ:PRTO)

Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company's product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *